Glioma is the most common fatal primary malignant brain tumor in the central nervous system (CNS). Currently, the main standard treatment is the combination of tumor resection, chemotherapy and radiotherapy. The World Health Organization (WHO) classifies glioma into four grades. Glioblastoma (GBM, WHO Grade 4) is the most aggressive type of glioma, characterized by cell heterogeneity, high proliferation rate, diffuse infiltration ability, and high resistance to chemotherapy drugs. Since the five-year survival rate is extremely low and the recurrence rate is high, some new effective treatment strategies are expected. Pyroptosis is an inflammatory programmed cell death mode. Compared with apoptosis, pyroptosis occurs faster and is accompanied by the release of a large number of pro-inflammatory factors. A large amount of evidence shows that pyrodeath can affect the development of tumor, and has both promoting and inhibiting effects on the development of glioma. In order to further understand the influence of pyroptosis on the glioma, this paper discussed the related studies of pyroptosis and glioma, in order to provide potential tumor treatment strategies based on pyroptosis for glioma patients.
| Published in | Cancer Research Journal (Volume 11, Issue 2) |
| DOI | 10.11648/j.crj.20231102.15 |
| Page(s) | 70-74 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Glioma, Pyroptosis, Programmed Death, Molecular Mechanism
| [1] | Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012 Nov; 14 Suppl 5: v1-49. |
| [2] | Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci. 2017 Apr; 42 (4): 245-254. |
| [3] | Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001 Mar; 9 (3): 113-4. |
| [4] | Tan Y, Chen Q, Li X, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021 May 3; 40 (1): 153. |
| [5] | Du T, Gao J, Li P, et al. Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med. 2021 Aug; 11 (8): e492. |
| [6] | de Vasconcelos NM, Van Opdenbosch N, Van Gorp H, et al. Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. Cell Death Differ. 2019 Jan; 26 (1): 146-161. |
| [7] | Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016 Jul 7; 535 (7610): 153-8. |
| [8] | Lagrange B, Benaoudia S, Wallet P, et al. Human caspase-4 detects tetra-acylated LPS and cytosolic Francisella and functions differently from murine caspase-11. Nat Commun. 2018 Jan 16; 9 (1): 242. |
| [9] | Fang Y, Tian S, Pan Y, et al. Pyroptosis: A new frontier in cancer. Biomed Pharmacother. 2020 Jan; 121: 109595. |
| [10] | Ding J, Wang K, Liu W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016 Jul 7; 535 (7610): 111-6. |
| [11] | Thi HTH, Hong S. Inflammasome as a Therapeutic Target for Cancer Prevention and Treatment. J Cancer Prev. 2017 Jun; 22 (2): 62-73. |
| [12] | Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020 Mar; 20 (3): 143-157. |
| [13] | Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015 Oct 29; 526 (7575): 666-71. |
| [14] | Zhang Y, He R, Lei X, et al. A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma. Front Genet. 2021 Nov 26; 12: 780780. |
| [15] | Zhou Y, Dai W, Wang H, et al. Long non-coding RNA CASP5 promotes the malignant phenotypes of human glioblastoma multiforme. Biochem Biophys Res Commun. 2018 Jun 12; 500 (4): 966-972. |
| [16] | Babas E, Ekonomopoulou MT, Karapidaki I, et al. Indication of participation of caspase-2 and caspase-5 in mechanisms of human cervical malignancy. Int J Gynecol Cancer. 2010 Nov; 20 (8): 1381-5. |
| [17] | Avrutsky MI, Troy CM. Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease. Front Pharmacol. 2021 Jul 9; 12: 701301. |
| [18] | Floyd DH, Zhang Y, Dey BK, et al. Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. PLoS One. 2014 May 7; 9 (5): e96239. |
| [19] | Shang J, Yang F, Wang Y, et al. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem. 2014 Apr; 115 (4): 772-84. |
| [20] | Liu J, Gao L, Zhu X, et al. Gasdermin D Is a Novel Prognostic Biomarker and Relates to TMZ Response in Glioblastoma. Cancers (Basel). 2021 Nov 10; 13 (22): 5620. |
| [21] | Zhang M, Cheng Y, Xue Z, et al. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration. BMC Cancer. 2021 Dec 7; 21 (1): 1311. |
| [22] | Bao HE, Wang F, Dou CW, et al. Effects of pyrodeath on the biological effects of glioma [J]. Chinese Journal of Medicine, 2012, 38: 3049-3053. |
| [23] | Jiang Z, Yao L, Ma H, et al. miRNA-214 Inhibits Cellular Proliferation and Migration in Glioma Cells Targeting Caspase 1 Involved in Pyroptosis. Oncol Res. 2017 Jul 5; 25 (6): 1009-1019. |
| [24] | Qiu S, Hu Y, Dong S. Pan-cancer analysis reveals the expression, genetic alteration and prognosis of pyroptosis key gene GSDMD. Int Immunopharmacol. 2021 Dec; 101 (Pt A): 108270. |
| [25] | Fan T, Wan Y, Niu D, et al. Comprehensive analysis of pyroptosis regulation patterns and their influence on tumor immune microenvironment and patient prognosis in glioma. Discov Oncol. 2022 Mar 10; 13 (1): 13. |
| [26] | Xiao Y, Zhang T, Ma X, et al. Microenvironment-Responsive Prodrug-Induced Pyroptosis Boosts Cancer Immunotherapy. Adv Sci (Weinh). 2021 Dec; 8 (24): e2101840. |
| [27] | Yang S, Xie C, Guo T, et al. Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-Dependent Pyroptosis in Glioblastoma Multiforme. World Neurosurg. 2022 Sep; 165: e12-e21. |
| [28] | Frontiers Editorial Office. Retraction: Downregulation of hsa_circ_0001836 Induces Pyroptosis Cell Death in Glioma Cells via Epigenetically Upregulating NLRP1. Front Oncol. 2021 Dec 29; 11: 840877. |
| [29] | Hu JJ, Liu X, Xia S, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020 Jul; 21 (7): 736-745. |
| [30] | Liu CC, Wu CL, Lin MX, et al. Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. Int J Mol Sci. 2021 Sep 28; 22 (19): 10496. |
| [31] | Lu C, Li X, Ren Y, et al. Disulfiram: a novel repurposed drug for cancer therapy. Cancer Chemother Pharmacol. 2021 Feb; 87 (2): 159-172. |
| [32] | Li L, Wu L, Yin X, et al. Bulk and Single-Cell Transcriptome Analyses Revealed That the Pyroptosis of Glioma-Associated Macrophages Participates in Tumor Progression and Immunosuppression. Oxid Med Cell Longev. 2022 Sep 26; 2022: 1803544. |
| [33] | Sharma N, Biswas S, Al-Dayan N, et al. Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants (Basel). 2021 Sep 5; 10 (9): 1419. |
| [34] | Chen S, Ma J, Yang L, et al. Anti-glioblastoma Activity of Kaempferol via Programmed Cell Death Induction: Involvement of Autophagy and Pyroptosis. Front Bioeng Biotechnol. 2020 Dec 10; 8: 614419. |
| [35] | Wu Y, Chang J, Ge J, et al. Isobavachalcone's Alleviation of Pyroptosis Contributes to Enhanced Apoptosis in Glioblastoma: Possible Involvement of NLRP3. Mol Neurobiol. 2022 Nov; 59 (11): 6934-6955. |
| [36] | Ren LW, Li W, Zheng XJ, et al. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta Pharmacol Sin. 2022 Jan; 43 (1): 194-208. |
| [37] | Tong L, Xie C, Wei Y, et al. Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release. Front Oncol. 2019 May 14; 9: 364. |
| [38] | Jorgensen I, Rayamajhi M, Miao EA. Programmed cell death as a defence against infection. Nat Rev Immunol. 2017 Mar; 17 (3): 151-164. |
| [39] | Wu L, Li L, Li S, et al. Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma. Acta Pharm Sin B. 2022 Oct; 12 (10): 3952-3971. |
| [40] | Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-"host"? Cell Death Dis. 2019 Sep 9; 10 (9): 650. |
| [41] | Evavold CL, Ruan J, Tan Y, et al. The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. Immunity. 2018 Jan 16; 48 (1): 35-44.e6. |
| [42] | Chen L, Huang CF, Li YC, et al. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018 Jun; 75 (11): 2045-2058. |
| [43] | Daley D, Mani VR, Mohan N, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med. 2017 Jun 5; 214 (6): 1711-1724. |
| [44] | Kaplanov I, Carmi Y, Kornetsky R, et al. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019 Jan 22; 116 (4): 1361-1369. |
| [45] | Ostrom QT, Patil N, Cioffi G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020 Oct 30; 22 (12 Suppl 2): iv1-iv96. |
APA Style
Xiaohui Han, Jie Zhou, Shihua Liu, Sen Yang, Aixia Sui. (2023). Research Progress on the Mechanism and Treatment of Pyroptosis in Brain Glioma. Cancer Research Journal, 11(2), 70-74. https://doi.org/10.11648/j.crj.20231102.15
ACS Style
Xiaohui Han; Jie Zhou; Shihua Liu; Sen Yang; Aixia Sui. Research Progress on the Mechanism and Treatment of Pyroptosis in Brain Glioma. Cancer Res. J. 2023, 11(2), 70-74. doi: 10.11648/j.crj.20231102.15
AMA Style
Xiaohui Han, Jie Zhou, Shihua Liu, Sen Yang, Aixia Sui. Research Progress on the Mechanism and Treatment of Pyroptosis in Brain Glioma. Cancer Res J. 2023;11(2):70-74. doi: 10.11648/j.crj.20231102.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.crj.20231102.15,
author = {Xiaohui Han and Jie Zhou and Shihua Liu and Sen Yang and Aixia Sui},
title = {Research Progress on the Mechanism and Treatment of Pyroptosis in Brain Glioma},
journal = {Cancer Research Journal},
volume = {11},
number = {2},
pages = {70-74},
doi = {10.11648/j.crj.20231102.15},
url = {https://doi.org/10.11648/j.crj.20231102.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20231102.15},
abstract = {Glioma is the most common fatal primary malignant brain tumor in the central nervous system (CNS). Currently, the main standard treatment is the combination of tumor resection, chemotherapy and radiotherapy. The World Health Organization (WHO) classifies glioma into four grades. Glioblastoma (GBM, WHO Grade 4) is the most aggressive type of glioma, characterized by cell heterogeneity, high proliferation rate, diffuse infiltration ability, and high resistance to chemotherapy drugs. Since the five-year survival rate is extremely low and the recurrence rate is high, some new effective treatment strategies are expected. Pyroptosis is an inflammatory programmed cell death mode. Compared with apoptosis, pyroptosis occurs faster and is accompanied by the release of a large number of pro-inflammatory factors. A large amount of evidence shows that pyrodeath can affect the development of tumor, and has both promoting and inhibiting effects on the development of glioma. In order to further understand the influence of pyroptosis on the glioma, this paper discussed the related studies of pyroptosis and glioma, in order to provide potential tumor treatment strategies based on pyroptosis for glioma patients.},
year = {2023}
}
TY - JOUR T1 - Research Progress on the Mechanism and Treatment of Pyroptosis in Brain Glioma AU - Xiaohui Han AU - Jie Zhou AU - Shihua Liu AU - Sen Yang AU - Aixia Sui Y1 - 2023/05/29 PY - 2023 N1 - https://doi.org/10.11648/j.crj.20231102.15 DO - 10.11648/j.crj.20231102.15 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 70 EP - 74 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20231102.15 AB - Glioma is the most common fatal primary malignant brain tumor in the central nervous system (CNS). Currently, the main standard treatment is the combination of tumor resection, chemotherapy and radiotherapy. The World Health Organization (WHO) classifies glioma into four grades. Glioblastoma (GBM, WHO Grade 4) is the most aggressive type of glioma, characterized by cell heterogeneity, high proliferation rate, diffuse infiltration ability, and high resistance to chemotherapy drugs. Since the five-year survival rate is extremely low and the recurrence rate is high, some new effective treatment strategies are expected. Pyroptosis is an inflammatory programmed cell death mode. Compared with apoptosis, pyroptosis occurs faster and is accompanied by the release of a large number of pro-inflammatory factors. A large amount of evidence shows that pyrodeath can affect the development of tumor, and has both promoting and inhibiting effects on the development of glioma. In order to further understand the influence of pyroptosis on the glioma, this paper discussed the related studies of pyroptosis and glioma, in order to provide potential tumor treatment strategies based on pyroptosis for glioma patients. VL - 11 IS - 2 ER -
Information
Email: